12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Company News  |  Deals

Genmab, Lundbeck deal

Genmab received a €1 million ($1.3 million) milestone payment from H. Lundbeck under a 2010 deal to use Genmab's technologies to discover and develop human antibody therapeutics against three targets selected by Lundbeck....

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >